FDES: neuroprotective aminoethanol derivative — RU2588365C1
Сергей Владимирович Оковитый, Евгений Борисович Шустов, Вера Цезаревна Болотова, Ирина Александровна Титович · 2016 · RU2588365C1 · patent family RU2588365C1
Published 2016-06-27.
Reported patent results
Reported findings
The patent reports longer survival in selected acute challenge models.
FDES aminoethanol-derivative studies in experimental brain-injury and acute oxygen-utilization models in animals.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Hemic-hypoxia model | Lifespan and survival described as 77% and 63% higher than control | The source does not clearly distinguish relative survival change from percentage-point change |
| Histotoxic-hypoxia model | Lifespan and survival described as 42% and 38% higher than control | Short animal challenge, not a chronic disease or patient survival outcome |
Do not convert the reported percentages into absolute survival probabilities. Acute animal challenge tolerance does not establish human neuroprotection, occupational safety or efficacy of ADK-17.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Molecule. This filing identifies the FDES candidate within the aminoethanol-derivative research collection.
FDES is not ADK-17; related chemical ancestry does not establish the same structure, claim coverage or clinical effects.
- Publication
- RU2588365C1 ↗ · 2016-06-27
- Earliest priority / filing
- Not established / 2015-05-19
- Original applicant / assignee
- Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА Минздрава России)
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Neuroprotective agent based on bis{2-[(2e)-4-hydroxy-4-oxobut-2-enoyloxy]-n,n-diethylethanamine}butandioate
Inventors: Сергей Владимирович Оковитый; Евгений Борисович Шустов; Вера Цезаревна Болотова; Ирина Александровна Титович.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- FDES is not ADK-17; related chemical ancestry does not establish the same structure, claim coverage or clinical effects.
- Do not convert the reported percentages into absolute survival probabilities. Acute animal challenge tolerance does not establish human neuroprotection, occupational safety or efficacy of ADK-17.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-RU2588365C1. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Сергей Владимирович Оковитый, Евгений Борисович Шустов, Вера Цезаревна Болотова, Ирина Александровна Титович. FDES: neuroprotective aminoethanol derivative — RU2588365C1 RU2588365C1 · patent family RU2588365C1 2016.
Molekul research summary: https://molekul.io/research/patent-ru2588365c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry